Objective: To assess the association between cytomegalovirus (CMV) IgG antibody levels, HIV disease progression, and immune activation markers.
Introduction
In resource-rich settings, cytomegalovirus (CMV) coinfection, viremia, subclinical shedding, and viral diversity are associated with an increased risk of progression to AIDS and death among persons living with HIV [1] [2] [3] [4] [5] [6] [7] . The humoral immune response to CMV, as measured by CMV-specific IgG antibody, has also been linked to untreated HIV disease progression in MSM [8, 9] . Despite use of antiretroviral therapy (ART), CMV coinfection is associated with increased risk of poor non-AIDS-related events [10] , and high CMV IgG antibody levels are associated with subclinical cardiovascular disease [11] , impaired neurocognitive function [12] , and decreased physical function [13] . Interestingly, similar findings have also been made among general populations in the United States and Europe [14] [15] [16] [17] .
The role of CMV coinfection in HIV pathogenesis is likely bidirectional [18] . HIV-induced immunosuppression might lead to increased CMV reactivation, which in turn can promote HIV replication and immune activation [18, 19] . Numerous investigations have suggested that CMV replication continues to drive CD8 þ T-cell expansion and inflammation in ART-experienced individuals [20] [21] [22] [23] [24] [25] . The cross-sectional evidence is conflicting in untreated and treated HIV-infected individuals, but some studies suggest that CMV IgG antibody levels may also be associated with immune activation markers, such as C-reactive protein (CRP) [13] , a general biomarker of systemic inflammation, and soluble CD14 (sCD14) [26] a biomarker of nonspecific monocyte activation [27] .
There are limited data on the role of CMV in chronic HIV disease in sub-Saharan Africa [28] [29] [30] . In this region, primary CMV infection predominantly occurs during infancy and is also associated with the development and maintenance of CD8 þ T-cell expansion during childhood [31] [32] [33] . By adulthood, CMV seroprevalence reaches close to 100% in most populations [29, 30] , so there is likely a high lifetime risk of reinfection before and during HIV infection. In addition to geographic variability in CMV shedding, CMV IgG antibody dynamics are known to differ by age, behavior, and host-genetics [22, 34] . Therefore, we aimed to assess the relationship between CMV IgG antibody levels, and HIV disease progression and immune activation in Rakai, Uganda.
Methods

Study design
Ugandan women coinfected with HIV-1 and herpes simplex virus type 2 (HSV-2), and a CD4 þ T-cell count between 300 and 400 cells/ml, were enrolled in a clinical trial to examine the effect of acyclovir on HIV disease progression over 24 months [35] . Individuals with AIDSdefining illnesses or those receiving ART were excluded. Participants were followed monthly for clinical screenings, drug refill, and adverse event review. Every 6 months, a physical examination was conducted and blood was drawn. Serum was stored at À80 8C. Participants provided written informed consent, and the study was approved by the Uganda Virus Research Institute Science and Ethics Committee, the Uganda National Council for Science and Technology, and the Institutional Review Board of the National Institute of Allergy and Infectious Diseases. The trial was registered with ClinicalTrials.gov (NCT00405821).
Laboratory testing CD4 þ T-cell counts, HIV viral load, sCD14, and highsensitivity CRP (hs-CRP) measurements were determined biannually [35, 36] . CMV IgG antibody levels were measured at the baseline visit among all women and at the 12-month and 24-month follow-up visits among a subset of women who initiated ART during the study period. CMV IgG antibody levels were measured up to a 1 : 200 dilution (CMV IgG Enzyme Immunoassay Test Kit, Genway Biotech; San Diego, California, USA).
Statistical analysis
Kaplan-Meier analysis and Cox proportional hazard models were used to assess the association between baseline CMV IgG tertiles and HIV disease progression (composite outcome: nontraumatic death, CD4 þ T-cell count 250 cells/ml, WHO Stage IV condition, or ART initiation by study clinicians for HIV-related symptoms). Participants were administratively censored at 24 months. The multivariable model included adjustment for study arm and potential baseline confounders: age, CD4
þ Tcell count, and HIV viral load. Other baseline covariates did not improve model fit as assessed by the likelihood ratio test and Akaike's information criterion.
In a sensitivity analysis, Cox regression with robust variance estimation was performed among a propensitymatched subcohort (based on the baseline CD4 þ T-cell count and HIV viral load) [37, 38] ; and the model was further adjusted for study arm and age. Greedy onenearest neighbor 1 : 1 matching on the propensity score was applied to select controls to compare with women in the high CMV IgG tertile group [37] .
Linear multilevel modeling with random effects for the intercept and slope were fitted to assess associations between baseline CMV IgG tertiles and annual changes in pre-ART levels of sCD14 and hs-CRP. Among women who initiated ART, random intercept models were used to examine the association of concurrent CMV IgG antibody levels (>median of post-ART visits) and sCD14 and hs-CRP.
Analyses were performed using STATA version 14.1 (StataCorp, College Station, Texas, USA) and R version 3.2 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Of 311 women enrolled in the trial, 300 had available sera at baseline and all were HIV/HSV-2/CMV coinfected. Lower CD4 þ T-cell counts at enrollment were observed among women in the higher baseline CMV IgG tertile groups (P ¼ 0.051). There was a positive association for HIV viral load, sCD14, and hs-CRP with increasing CMV IgG tertiles at baseline (P < 0.05; Table 1 ).
All participants contributed a total of 426.4 person-years with a median follow-up time of 1.81 years, and 150 women reached a primary endpoint (including nine nontraumatic deaths). Ten women were lost to follow-up, of which five were in the highest CMV IgG tertile. Compared with women in the low CMV IgG tertile at baseline, women in the highest CMV IgG tertile had a greater cumulative probability of reaching an endpoint (P log-rank < 0.001; Fig. 1a In an analysis of 1200 person-visits right-censored for ART initiation, baseline CMV IgG antibody levels were associated with annual changes in immune activation markers independent of time-updated CD4 þ T-cell count, log 10 HIV viral load, and a study arm and time interaction. Women in the low CMV IgG tertile at baseline had annual decreases in sCD14 [b ¼ À158.6 ng/ml/year (SE ¼ 69. þ T-cell count. In a subanalysis of women with virologic suppression (<400 copies/ml; n ¼ 88 personvisits), the adjusted difference in sCD14 and hs-CRP levels by the median level of CMV IgG antibody remained significant (P < 0.05).
Discussion
In this prospective study, elevated CMV IgG antibody levels at baseline were associated with untreated HIV disease progression in Rakai, Uganda. Elevated CMV IgG antibody levels at baseline were also associated with higher levels and annual increases in pre-ART sCD14 and hs-CRP levels. Subclinical CMV replication during HIV infection (prior to clinical AIDS) is common [25, 39] and, in a previous study among women nested in this cohort, we noted that 59% of women had detectable vaginal CMV shedding during the 6-month interval prior to ART initiation [40] . Taken together, these data support the hypothesis that CMV may contribute to systemic immune activation during untreated HIV infection and may be a cofactor in HIV disease progression in subSaharan Africa.
The increase in CMV IgG antibody levels after ART may indeed be due to immune reconstitution [41] , but also may in part be reflective of a subclinical immune reconstitution inflammatory effect [42] . Among women þ T-cell count, and HIV viral load at baseline, and the referent was the lowest baseline cytomegalovirus IgG tertile. The propensity-matched analysis accounted for CD4 þ T-cell count and HIV viral load at baseline, and the Cox regression model was further adjusted for study arm and age group. See the 'Methods' section for derivation of the propensity-matched control group. Ã P < 0.05.
nested in this cohort, we previously observed an increase in vaginal CMV shedding 2-4 months following ART initiation and that vaginal CMV shedding was associated with elevated vaginal markers of immune activation [40, 43] . Similarly, among women on ART for a median of 4-5 months, we noted that elevated post-ART CMV IgG antibody levels were associated with higher plasma immune activation markers. There is considerable variability between studies in precisely which immune activation markers are associated with post-ART CMV IgG levels [11, 13, 26, [44] [45] [46] [47] , but our findings are consistent with the model suggesting that CMV has a role in driving persistent immune activation during suppressive ART [25] . The durability of these associations requires confirmation during long-term ART use.
The current study has limitations. Due to the high prevalence of CMV among adults in sub-Saharan Africa, it is difficult to directly estimate the effect of CMV coinfection on chronic HIV disease. We therefore measured CMV IgG antibody levels; however, this biomarker cannot be directly interpreted as a surrogate for CMV replication in HIV-infected individuals [48] . As discussed elsewhere [19, 22, 25] , CMV IgG antibody levels may reflect one or a combination of the following: lifetime burden of CMV replication and reinfection, recent CMV reactivation or reinfection, or strength of the host immune response to suppress low-level CMV replication. As we had limited knowledge of other coinfections and did not measure B-cell activation markers or total IgG levels, we cannot exclude the potential for residual confounding, particularly due to aberrant B-cell activation. Notably, however, a previous study demonstrated increases in CMV-specific IgG antibody levels during HIV infection that were not seen for IgG levels specific to other coinfections [49] , and weak correlations have been observed between total IgG levels and CMV lysate antibody levels among HIV-infected individuals on ART [12] . It should also be noted that the results from this study may not be generalizable to men or resource-rich settings.
In summary, the magnitude of the CMV-specific humoral immune response was associated with HIV disease progression and immune activation among Ugandan women living with HIV. The role of CMV during chronic HIV infection warrants further investigation in sub-Saharan Africa.
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